Sanofi India Ltd - 500674 - Loss of Share Certificate / Issue of Duplicate Share Certificate
Sanofi India Ltd has informed BSE regarding Loss of Share Certificate / Issue of Duplicate Share Certificate.14-01-2019
Sanofi India Ltd - 500674 - Loss of Share Certificate / Issue of Duplicate Share Certificate
Sanofi India Ltd has informed BSE regarding Loss of Share Certificate / Issue of Duplicate Share Certificate.Sanofi India Ltd - 500674 - Statement Of Investor Complaints For The Quarter Ended December 2018
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0440 Name of the Signatory :- GIRISH TEKCHANDANIDesignation :- Company Secretary and Compliance OfficerSanofi India Ltd - 500674 - Loss of Share Certificate / Issue of Duplicate Share Certificate
Sanofi India Ltd has informed BSE regarding Loss of Share Certificate / Issue of Duplicate Share Certificate.Sanofi India Ltd - 500674 - Shareholding for the Period Ended December 31, 2018
Sanofi India Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2018. For more details, kindly Click hereSanofi India Ltd - 500674 - Loss of Share Certificate / Issue of Duplicate Share Certificate
Sanofi India Ltd has informed BSE regarding Loss of Share Certificate / Issue of Duplicate Share Certificate.Sanofi India Ltd - 500674 - Loss of Share Certificate / Issue of Duplicate Share Certificate
Sanofi India Ltd has informed BSE regarding Loss of Share Certificate / Issue of Duplicate Share Certificate.Sanofi acts after polio vaccine found in private market
PT Jyothi DattaVaccine-maker Sanofi Pasteur has initiated action at multiple levels after vials of Shan IPV, its inactivated polio vaccine meant onlyClarification On The Media Report In The Indian Express
This has reference to your email dated 12th November 2018 on the above subject. We would like to inform you that we have recalled stocks of one batch of Lasix from the market based on the directive issued by Kerala Drug Control department. Our control samples are in line with defined quality parameters and do not show any deviation. We are investigating the matter and have no further details to add at this stage....Clarification sought from Sanofi India Ltd
The Exchange has sought clarification from Sanofi India Ltd with respect to news article appearing on indianexpress.com - November 11, 2018 titled "Kerala regulator finds three drugs to be of substandard quality". The reply is awaited.Sanofi India net marginally up
Drug firm Sanofi India on Wednesday reported a 2.49 per cent rise in its net profit to 119.2 crore for the quarter ended September 2018 against a n